United Health Products
United Health Products, Inc. (OTC: UEEC) is a medical device company developing HemoStyp — a hemostatic gauze product made from a proprietary plant-based material that promotes rapid blood clotting and wound healing for surgical, traumatic, and chronic wound applications. According to its website at unitedhealthproducts.com, HemoStyp's unique biocompatible material promotes hemostasis — the process of stopping bleeding — through physical and biological mechanisms that activate the blood clotting cascade when applied to bleeding wounds, with the added benefit of a naturally derived material that is biocompatible and can support wound healing. United Health Products has pursued FDA clearance for HemoStyp for multiple wound care applications, targeting surgical wound management, traumatic wound care, and other clinical settings where effective, rapid hemostasis is a critical clinical requirement.
United Health Products' HemoStyp hemostatic gauze technology, described at unitedhealthproducts.com, is developed from a modified plant-based fiber material that has been processed to create a hemostatic gauze with the physical and surface chemistry characteristics required to effectively interact with the blood coagulation system and promote rapid clot formation at the wound site. The material's biocompatibility and wound healing support properties — in addition to its hemostatic function — differentiate HemoStyp from some conventional hemostatic dressings whose materials may require removal before wound healing can progress efficiently. United Health Products has conducted laboratory and clinical studies evaluating HemoStyp's hemostatic performance in surgical and wound care applications, generating the safety and efficacy data required to support FDA regulatory submissions.
United Health Products is publicly traded on the OTC markets and pursues the regulatory clearance and commercialization of HemoStyp through FDA 510(k) submissions and engagement with the FDA on the clinical evidence requirements for hemostatic wound dressing clearance. According to unitedhealthproducts.com, the company's commercialization strategy targets surgical, emergency medicine, and wound care settings where HemoStyp's hemostatic properties and biocompatible material characteristics can provide clinical advantages over conventional hemostatic dressings and gauzes. United Health Products' combination of plant-based hemostatic gauze technology, wound healing biocompatibility focus, FDA regulatory clearance pursuit, surgical and wound care market targeting, and OTC-listed public company structure reflects its positioning as a development-stage medical device company pursuing regulatory approval of a novel hemostatic wound care product.